Imperial College London
Alternate

DrZacharyWhinnett

Faculty of Medicine, National Heart & Lung Institute

Reader in Cardiac Electrophysiology
 
 
 
//

Contact

 

z.whinnett

 
 
//

Location

 

South- NHLI Cardiovascular ScienceBlock B Hammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Keene:2018:10.1002/ehf2.12315,
author = {Keene, D and Arnold, A and Shun-Shin, MJ and Howard, JP and Sohaib, SA and Moore, P and Tanner, M and Quereshi, N and Muthumala, A and Chandresekeran, B and Foley, P and Leyva, F and Adhya, S and Falaschetti, E and Tsang, H and Vijayaraman, P and Cleland, JGF and Stegemann, B and Francis, DP and Whinnett, ZI},
doi = {10.1002/ehf2.12315},
journal = {ESC Heart Failure},
pages = {965--976},
title = {Rationale and design of the randomized multicentre His Optimized Pacing Evaluated for Heart Failure (HOPE-HF) trial},
url = {http://dx.doi.org/10.1002/ehf2.12315},
volume = {5},
year = {2018}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - AIMS: In patients with heart failure and a pathologically prolonged PR interval, left ventricular (LV) filling can be improved by shortening atrioventricular delay using His-bundle pacing. His-bundle pacing delivers physiological ventricular activation and has been shown to improve acute haemodynamic function in this group of patients. In the HOPE-HF (His Optimized Pacing Evaluated for Heart Failure) trial, we are investigating whether these acute haemodynamic improvements translate into improvements in exercise capacity and heart failure symptoms. METHODS AND RESULTS: This multicentre, double-blind, randomized, crossover study aims to randomize 160 patients with PR prolongation (≥200 ms), LV impairment (EF ≤ 40%), and either narrow QRS (≤140 ms) or right bundle branch block. All patients receive a cardiac device with leads positioned in the right atrium and the His bundle. Eligible patients also receive a defibrillator lead. Those not eligible for implantable cardioverter defibrillator have a backup pacing lead positioned in an LV branch of the coronary sinus. Patients are allocated in random order to 6 months of (i) haemodynamically optimized dual chamber His-bundle pacing and (ii) backup pacing only, using the non-His ventricular lead. The primary endpoint is change in exercise capacity assessed by peak oxygen uptake. Secondary endpoints include change in ejection fraction, quality of life scores, B-type natriuretic peptide, daily patient activity levels, and safety and feasibility assessments of His-bundle pacing. CONCLUSIONS: Hope-HF aims to determine whether correcting PR prolongation in patients with heart failure and narrow QRS or right bundle branch block using haemodynamically optimized dual chamber His-bundle pacing improves exercise capacity and symptoms. We aim to complete recruitment by the end of 2018 and report in 2020.
AU  - Keene,D
AU  - Arnold,A
AU  - Shun-Shin,MJ
AU  - Howard,JP
AU  - Sohaib,SA
AU  - Moore,P
AU  - Tanner,M
AU  - Quereshi,N
AU  - Muthumala,A
AU  - Chandresekeran,B
AU  - Foley,P
AU  - Leyva,F
AU  - Adhya,S
AU  - Falaschetti,E
AU  - Tsang,H
AU  - Vijayaraman,P
AU  - Cleland,JGF
AU  - Stegemann,B
AU  - Francis,DP
AU  - Whinnett,ZI
DO  - 10.1002/ehf2.12315
EP  - 976
PY  - 2018///
SN  - 2055-5822
SP  - 965
TI  - Rationale and design of the randomized multicentre His Optimized Pacing Evaluated for Heart Failure (HOPE-HF) trial
T2  - ESC Heart Failure
UR  - http://dx.doi.org/10.1002/ehf2.12315
UR  - https://www.ncbi.nlm.nih.gov/pubmed/29984912
UR  - https://onlinelibrary.wiley.com/doi/full/10.1002/ehf2.12315
UR  - http://hdl.handle.net/10044/1/60923
VL  - 5
ER  -
Download